OBJECTIVES: We sought to determine if an underlying mechanism of the association between prolonged symptom-to-treatment times and adverse outcomes may be an association of symptom-to-treatment times with impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades (TMPGs). BACKGROUND: Prolonged symptom duration among ST-segment elevation myocardial infarction (STEMI) patients undergoing fibrinolytic therapy is associated with adverse outcomes. METHODS: Angiography was performed 60 min after fibrinolytic administration in 3,845 Thrombolysis In Myocardial Infarction (TIMI) trial patients. RESULTS: The median time from symptom onset to treatment was longer among patients with impaired myocardial perfusion (3.0 h for TMPG 0/1 vs. 2.7 h for TMPG 2/3; p = 0.001). In a multivariate model, impaired tissue perfusion (TMPG 0/1) remained associated with increased time to treatment (odds ratio 1.14 per hour of delay; p = 0.007) even after adjusting for Thrombolysis In Myocardial Infarction flow grade (TFG) 3, left anterior descending infarct location, and baseline clinical characteristics. Impaired myocardial perfusion after rescue/adjunctive percutaneous coronary intervention (PCI) was associated with longer median times to treatment (3.0 h for TMPG 2/3 vs. 2.7 h for TMPG 0/1; p = 0.017), as was abnormal epicardial flow after rescue/adjunctive PCI (3.3 h for TFG 0/1/2 vs. 2.8 h for TFG 3; p = 0.005). Thirty-day mortality was associated with longer time from onset of symptoms to treatment (6.6% mortality for time to treatment >4 h vs. 3.3%; p < 0.001), even among patients undergoing rescue PCI. CONCLUSIONS: A prolonged symptom to treatment time among STEMI patients is associated with impaired myocardial perfusion independent of epicardial flow both immediately after fibrinolytic administration and after rescue/adjunctive PCI. These data provide a pathophysiologic link between prolonged symptoms due to vessel occlusion, impaired myocardial perfusion, and poor clinical outcomes.
OBJECTIVES: We sought to determine if an underlying mechanism of the association between prolonged symptom-to-treatment times and adverse outcomes may be an association of symptom-to-treatment times with impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades (TMPGs). BACKGROUND: Prolonged symptom duration among ST-segment elevation myocardial infarction (STEMI) patients undergoing fibrinolytic therapy is associated with adverse outcomes. METHODS: Angiography was performed 60 min after fibrinolytic administration in 3,845 Thrombolysis In Myocardial Infarction (TIMI) trial patients. RESULTS: The median time from symptom onset to treatment was longer among patients with impaired myocardial perfusion (3.0 h for TMPG 0/1 vs. 2.7 h for TMPG 2/3; p = 0.001). In a multivariate model, impaired tissue perfusion (TMPG 0/1) remained associated with increased time to treatment (odds ratio 1.14 per hour of delay; p = 0.007) even after adjusting for Thrombolysis In Myocardial Infarction flow grade (TFG) 3, left anterior descending infarct location, and baseline clinical characteristics. Impaired myocardial perfusion after rescue/adjunctive percutaneous coronary intervention (PCI) was associated with longer median times to treatment (3.0 h for TMPG 2/3 vs. 2.7 h for TMPG 0/1; p = 0.017), as was abnormal epicardial flow after rescue/adjunctive PCI (3.3 h for TFG 0/1/2 vs. 2.8 h for TFG 3; p = 0.005). Thirty-day mortality was associated with longer time from onset of symptoms to treatment (6.6% mortality for time to treatment >4 h vs. 3.3%; p < 0.001), even among patients undergoing rescue PCI. CONCLUSIONS: A prolonged symptom to treatment time among STEMI patients is associated with impaired myocardial perfusion independent of epicardial flow both immediately after fibrinolytic administration and after rescue/adjunctive PCI. These data provide a pathophysiologic link between prolonged symptoms due to vessel occlusion, impaired myocardial perfusion, and poor clinical outcomes.
Authors: Gregory M Ouellet; Mary Geda; Terrence E Murphy; Sui Tsang; Mary E Tinetti; Sarwat I Chaudhry Journal: J Am Geriatr Soc Date: 2017-10-18 Impact factor: 5.562
Authors: Terje K Steigen; Christopher E Buller; G B John Mancini; Vinod Jorapur; Warren J Cantor; James M Rankin; Boban Thomas; John G Webb; Shari S Kronsberg; Deborah J Atchison; Gervasio A Lamas; Judith S Hochman; Vladimír Džavík Journal: Circ Cardiovasc Interv Date: 2010-11-09 Impact factor: 6.546
Authors: Robert L McNamara; Jeph Herrin; Yongfei Wang; Jeptha P Curtis; Elizabeth H Bradley; David J Magid; Saif S Rathore; Brahmajee K Nallamothu; Eric D Peterson; Martha E Blaney; Paul Frederick; Harlan M Krumholz Journal: Am J Cardiol Date: 2007-08-01 Impact factor: 2.778
Authors: Henry H Ting; Elizabeth H Bradley; Yongfei Wang; Judith H Lichtman; Brahmajee K Nallamothu; Mark D Sullivan; Bernard J Gersh; Veronique L Roger; Jeptha P Curtis; Harlan M Krumholz Journal: Arch Intern Med Date: 2008-05-12
Authors: Vinod Jorapur; Terje K Steigen; Christopher E Buller; Vladimír Dzavík; John G Webb; Bradley H Strauss; Eunice E S Yeoh; Peter Kurray; Leszek Sokalski; Mauricio C Machado; Shari S Kronsberg; Gervasio A Lamas; Judith S Hochman; G B John Mancini Journal: Catheter Cardiovasc Interv Date: 2008-11-15 Impact factor: 2.692
Authors: Henry H Ting; Elizabeth H Bradley; Yongfei Wang; Brahmajee K Nallamothu; Bernard J Gersh; Veronique L Roger; Judith H Lichtman; Jeptha P Curtis; Harlan M Krumholz Journal: Am J Med Date: 2008-04 Impact factor: 4.965
Authors: Karl Heinrich Scholz; Thomas Meyer; Björn Lengenfelder; Christian Vahlhaus; Jörn Tongers; Steffen Schnupp; Rainer Burckhard; Nicolas von Beckerath; Hans-Martin Grusnick; Andreas Jeron; Klaus Dieter Winter; Sebastian K G Maier; Michael Danner; Jürgen Vom Dahl; Stefan Neef; Stefan Stefanow; Tim Friede Journal: Open Heart Date: 2021-05
Authors: David Weininger; Juan Pablo Cordova; Eelin Wilson; Dayana J Eslava; Carlos L Alviar; Aleksandr Korniyenko; Chirag Pankajkumar Bavishi; Mun K Hong; Amy Chorzempa; John Fox; Jacqueline E Tamis-Holland Journal: Ther Clin Risk Manag Date: 2022-01-04 Impact factor: 2.423